A Research Study of the New Medicine NNC0519-0130 in Male Chinese Participants Living With Excess Body Weight

Launched by NOVO NORDISK A/S · May 26, 2025

Keywords

ClinConnect Summary

This clinical trial is testing a new medicine called NNC0519-0130, developed by Novo Nordisk, for men living in China who have type 2 diabetes and are overweight. The goal is to see how well this new medicine works and how safe it is for participants. During the study, some men will receive the actual medicine, while others will get a placebo, which is a harmless substance that looks like the medicine but has no active ingredients. The trial will last about 28 weeks and will test different doses of NNC0519-0130 to find the best one.

To be eligible for this trial, participants must be male, between the ages of 18 and 75, and have a body mass index (BMI) of 24 to 39.9, meaning they are overweight. They should also be in generally good health, without any serious medical conditions that might affect their safety. Participants can expect to undergo some health checks before starting the trial, including tests on their heart and blood. It’s important to know that this study is not yet recruiting, so interested individuals will have to wait for further announcements about when they can join.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • Male Chinese participant.
• • Body Mass Index (BMI) between 24.0 and 39.9 kilogram per square meter (kg/m\^2) (both inclusive) at screening. Overweight should be due to excess adipose tissue, as judged by the investigator.
• • Considered eligible based on the medical history, physical examination, and the results of vital signs, electrocardiogram (ECG) and clinical laboratory tests performed during the screening visit, as judged by the investigator.
• Exclusion Criteria:
• • Any disorder which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol.
• • Presence or history of any clinically relevant respiratory, metabolic, renal, hepatic, cardiovascular, gastrointestinal, or endocrinological conditions.
• • Glycated haemoglobin (HbA1c) greater than or equal to (≥) 6.5 percentage (%) (48 millimoles per mole \[mmol/mol\]) at screening.
• • Use of prescription medicinal products or non-prescription drugs (including Chinese traditional medicine or local medicine) within 14 days before screening, except routine vitamins, occasional use of paracetamol, ibuprofen, acetylsalicylic acid (ASA), domperidone or topical medication.